Cargando…
Orphan Drug Pricing and Costs: A Case Study of Kalydeco and Orkambi
BACKGROUND: A common narrative is that high prices are necessary for “orphan drugs” because of the fewer patients. In the context of state health insurance systems, the high prices create significant challenges because of limited budgets. RESULTS: This study carefully examines both costs and revenue...
Autor principal: | Hollis, Aidan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Longwoods Publishing
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7008693/ https://www.ncbi.nlm.nih.gov/pubmed/31629457 http://dx.doi.org/10.12927/hcpol.2019.25937 |
Ejemplares similares
-
Estimating the clinical cost of drug development for orphan versus non-orphan drugs
por: Jayasundara, Kavisha, et al.
Publicado: (2019) -
Variables affecting pricing of orphan drugs: the Italian case
por: Jommi, Claudio, et al.
Publicado: (2021) -
Proximity Profiling of the CFTR Interaction Landscape in Response to Orkambi
por: Iazzi, Melissa, et al.
Publicado: (2022) -
The impact of early phase price agreements on prices of orphan drugs
por: Nuijten, Mark, et al.
Publicado: (2021) -
Establishing a reasonable price for an orphan drug
por: Berdud, Mikel, et al.
Publicado: (2020)